Lyka Labs Limited (NSE:LYKALABS) — Market Cap & Net Worth
Market Cap & Net Worth: Lyka Labs Limited (LYKALABS)
Lyka Labs Limited (NSE:LYKALABS) has a market capitalization of $31.54 Million (Rs2.92 Billion) as of September 19, 2026. Listed on the NSE stock exchange, this India-based company holds position #23690 globally and #1307 in its home market, demonstrating a 0.25% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lyka Labs Limited's stock price Rs81.71 by its total outstanding shares 35690000 (35.69 Million). Also see Lyka Labs Limited total assets for a full breakdown of the balance sheet.
Lyka Labs Limited Market Cap History: 2015 to 2026
Lyka Labs Limited's market capitalization history from 2015 to 2026. Data shows change from $49.50 Million to $31.54 Million (-1.03% CAGR). Also see LYKALABS cash flow conversion for how efficiently the company converts equity into cash flow.
Lyka Labs Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lyka Labs Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Lyka Labs Limited stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.02x
Lyka Labs Limited's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.37x
Lyka Labs Limited's market cap is 0.37 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $20.57 Million | $1.28 Billion | $36.87 Million | 0.02x | 0.56x |
| 2017 | $24.86 Million | $993.80 Million | -$55.38 Million | 0.03x | N/A |
| 2018 | $11.71 Million | $563.60 Million | -$172.75 Million | 0.02x | N/A |
| 2019 | $7.57 Million | $642.38 Million | -$55.50 Million | 0.01x | N/A |
| 2020 | $11.97 Million | $554.08 Million | -$605.41 Million | 0.02x | N/A |
| 2021 | $85.49 Million | $671.07 Million | -$115.55 Million | 0.13x | N/A |
| 2022 | $50.06 Million | $1.84 Billion | $390.00 Million | 0.03x | 0.13x |
| 2023 | $47.76 Million | $916.90 Million | -$132.12 Million | 0.05x | N/A |
| 2024 | $60.91 Million | $1.05 Billion | -$24.89 Million | 0.06x | N/A |
| 2025 | $29.29 Million | $1.41 Billion | $80.12 Million | 0.02x | 0.37x |
Competitor Companies of LYKALABS by Market Capitalization
Companies near Lyka Labs Limited in the global market cap rankings as of September 19, 2026. Review tangible equity quality of Lyka Labs Limited to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Lyka Labs Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Lyka Labs Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Lyka Labs Limited's market cap moved from $49.50 Million to $ 31.54 Million, with a yearly change of -1.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs31.54 Million | +7.67% |
| 2025 | Rs29.29 Million | -51.91% |
| 2024 | Rs60.91 Million | +27.53% |
| 2023 | Rs47.76 Million | -4.59% |
| 2022 | Rs50.06 Million | -41.44% |
| 2021 | Rs85.49 Million | +614.52% |
| 2020 | Rs11.97 Million | +58.16% |
| 2019 | Rs7.57 Million | -35.42% |
| 2018 | Rs11.71 Million | -52.87% |
| 2017 | Rs24.86 Million | +20.83% |
| 2016 | Rs20.57 Million | -58.44% |
| 2015 | Rs49.50 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Lyka Labs Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $31.54 Million USD |
| MoneyControl | $31.54 Million USD |
| MarketWatch | $31.54 Million USD |
| marketcap.company | $31.54 Million USD |
| Reuters | $31.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lyka Labs Limited
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-d… Read more